摘要
糖尿病患者倾向于早期发生广泛弥漫的动脉粥样硬化,而其确切机制尚未完全阐明。有研究提示低密度脂蛋白的氧化加速了糖尿病大血管病变的进程,凝集素样氧化型低密度脂蛋白受体1是一种新型氧化型低密度脂蛋白受体,糖尿病中血管内皮细胞凝集素样氧化型低密度脂蛋白受体1呈表达上调状态,而且可溶性凝集素样氧化型低密度脂蛋白受体1有可能成为血管性疾病的生物学指标。多项研究提示治疗2型糖尿病的相关药物可抑制凝集素样氧化型低密度脂蛋白受体1的表达。本文就凝集素样氧化型低密度脂蛋白受体1在糖尿病大血管病变中的作用、调节机制及干预措施作一综述。
Diabetic subjects exhibit an increased propensity to develop a diffuse and extensive pattern of arteriosclerosis.However,its mechanisms are still poorly understood.There is evidence to suggest that oxidization of low density lipoprotein（LDL）accelerated the progression of diabetic vasculopathy.Lectin-like oxidized low density lipoprotein receptor-1（LOX-1）is a newly identified receptor for oxidized LDL and it is up-regulated in diabetic condition.Some studies have shown that drugs commonly used in the treatment of diabetic patients inhibit endothelial LOX-1 expression.This review summarizes the function of LOX-1 in diabetic macrovascular disease,its regulation mechanisms and therapeutic approaches.
出处
《中国动脉硬化杂志》
CAS
CSCD
北大核心
2010年第3期249-252,共4页
Chinese Journal of Arteriosclerosis
